Posted on

A dose a day keeps the brain fog away

Mindset Pharma Announces Preclinical Results Demonstrating Extended Duration of Action in its Long-Acting Next Generation Psychedelic Compounds

Can you get the benefits of psilocybin without the trip? That’s what Mindset Pharma Inc. (MSET) is trying to determine.

The company recently developed a family of psilocybin analogs designed for microdosing. In preclinical studies, the compounds were found to have about 1/10th of the effect on 5-HT2A receptors as psilocybin, but with extended duration, which indicates that they will be ideal for once a day or once every other day dosing.

Mindset plans to test the compounds in preclinical animal models to determine if microdosing has cognitive enhancing effects.

 

 

PDF of article

Posted on

Kick your cravings

TRYP THERAPEUTICS COMPLETES PSYCHOTHERAPY TRAINING FOR PHASE 2A STUDY AT THE UNIVERSITY OF FLORIDA

The nausea from shrooms can make you not want to eat, but can they prevent over-eating even after the trip is over?

A University of Florida study conducted by Tryp Therapeutics (TRYP) will reveal the answer. This week, the company finished training its psychotherapists for an upcoming Phase 2a clinical trial on over-eating disorders. The training was led by a psychedelic therapy training company called Fluence.

The patients will receive two doses of TRP-8802, Tryp’s oral formulation of synthetic psilocybin, in addition to preparation and integration sessions.

Posted on

Rolling the dice on a new treatment method

Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling Addiction Led by Professor Celia Morgan

Psilocybin isn’t the only psychedelic that’s being studied for addiction treatment!

Awakn Life Sciences (AWKN) has received approval for the first-ever study on ketamine in gambling addiction –  a disorder that affects 10 million people in the US alone, yet has no licensed pharmacological treatment.

The company will use ketamine-assisted psychotherapy to tackle the urge to gamble as well as superstitious thinking that’s at the root of the addition.

Awakn is also investigating the effects of ketamine and MDMA in treating alcohol use disorder (AUD).

Posted on

Therapists need drugs too

Clinical Trial Application Submitted to Health Canada for Experiential, Psychedelic-Assisted Psychotherapy Training

Before a therapist can guide patients through psychedelic therapy, it’s pretty important that they know what the drugs feel like firsthand.

There’s a growing demand for experiential training for mental health professionals, and organizations in both Canada and the US are starting to fill this gap.

ATMA Journey Centers, a clinic in Calgary, submitted an application to Health Canada for an experiential-based clinical trial to train mental health providers looking to offer psychedelic-assisted therapy –  and there are currently 400 professionals on the waitlist.

The study will assess the psychological effects of psilocybin in healthy patients, as well as physiological effects like heart rate, blood pressure, and body temperature. Since most psilocybin studies are conducted on patients with mental health disorders, this trial will produce much-needed ‘healthy control’ data to use as a baseline.

In the US, two psychotherapists just founded the Psychedelic Coalition for Health (PCH) to offer experiential psychedelic integration training for professionals.

PDF of article

 

Posted on

Finally some research on microdosing

Diamond Therapeutics Announces Health Canada Approval of Clinical Trial with Low-Dose Psilocybin 

There’s tremendous anecdotal evidence that microdosing has therapeutic benefits, yet there’s limited research on its effects. Luckily, that’s starting to change thanks to Diamond Therapeutics.

The Toronto-based company received Health Canada approval to conduct a Phase 1 human clinical trial to evaluate low doses of psilocybin in up to 80 healthy volunteers. The preclinical research suggests that low, non-hallucinogenic doses have potential therapeutic benefits.

Diamond Therapeutics is also planning to conduct a Phase 2 trial in the US and Canada to evaluate low psilocybin doses in treating anxiety and will support an investigator-led study on moderate depression as well.

PDF of article

Posted on

Make your New Year’s resolutions stick

Awakn Life Sciences Expands World’s First Ketamine Study Beyond Gambling Disorder To Include Additional Behavioral Addictions

Spent too much time gaming or had too much sex in 2021? 

We’re guessing you didn’t answer yes to both, but if you struggle with one of these things, ketamine therapy could help you make changes this year 😉

Awakn Life Sciences (AWKN) received ethics approval to expand its ketamine study. In addition to investigating Gambling Disorder, it will now cover three more behavioral addictions: Internet Gaming Disorder, Compulsive Sexual Behaviour, and Binge Eating Disorder.

The goal is to “harness a window in which the brain is able to make new connections” to create lasting behaviour changes. 

PDF of article

logo
Posted on

psilera

Psilera Initiates Landmark Preclinical Studies with New Psychedelic Derivatives aimed at Reducing Alcohol Consumption

If you developed a drinking problem during the pandemic, you’re not alone. Alcohol use disorder (AUD) affects 283 million people and growing, which is why Psilera Inc. is studying psilocybin’s anti-addictive properties.

The Florida biotech company launched a new preclinical study that will assess up to seven psychedelic-inspired new chemical entities (NCE) on reducing alcohol consumption. The company aims to limit the psychedelic effects of the drugs to potentially allow administration outside of a clinical setting.

PDF of article

Posted on

Taking the trip out of psilocybin

Nova Mentis Files Fragile X Orphan Drug Designation with European Medicines Agency

Fragile x syndrome (FXS) is the leading genetic cause of autism spectrum disorder (ASD) symptoms, yet there is currently no approved prevention or treatment options. Nova Mentis (NOVA) is working to fill this gap with a non-psychedelic psilocybin-based drug.

The company announced that its proprietary psilocybin drug, NM1010, was able to improve cognition without a creating psychedelic effect in a preclinical model of FXS. In tests on animals, the drug showed improvements in inflammatory biomarkers that may be linked to the ASD disease process.

The company has filed for orphan drug designation with the European Medicines Agency (EMA), a status that gives companies exclusive rights and tax credits to incentive the development of treatments for diseases affecting ≤ 5 in 10,000 people.

Posted on

It might be time to switch your meds

Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports

If you take this medication, you may want to avoid psychedelics.

A new analysis from Johns Hopkins researchers suggests that psychedelics could increase seizure risk in people taking lithium, a common bipolar medication. The researchers analyzed online self-reports from sites like Reddit and Shroomery and found that 29 of 62 reports combining the drugs resulted in seizures, and an additional 11 reported bad trips.

On the bright side, there were no reports of seizures or bad trips out of the 34 cases involving psychedelics and a different bipolar medication called lamotrigine.

PDF of article

Posted on

Prevent wrinkles ;) … and cancer

Anti-Inflammatory Effects of Four Psilocybin-Containing Magic Mushroom Water Extracts in vitro on 15-Lipoxygenase Activity and on Lipopolysaccharide-Induced Cyclooxygenase-2 and Inflammatory Cytokines in Human U937 Macrophage Cells

Mushroom tea could be the secret to aging gracefully.

Aging, as well as several chronic diseases like cancer, arthritis, neurodegeneration, chronic depression, and cardiovascular disease, are often tied to pathological inflammation.

A new study from a South African university revealed that psilocybin mushrooms have potent anti-inflammatory properties that could help treat chronic these conditions. Researchers analyzed 4 species of psilocybin mushrooms, which were extracted in hot water, and discovered that they suppressed the body’s inflammatory response by inhibiting several inflammatory proteins.

PDF of study